Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Baker Tilly Wealth Management LLC

Baker Tilly Wealth Management LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,573 shares of the biopharmaceutical company’s stock after selling 735 shares during the quarter. Baker Tilly Wealth Management LLC’s holdings in Gilead Sciences were worth $515,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. First Hawaiian Bank grew its position in Gilead Sciences by 0.3% during the fourth quarter. First Hawaiian Bank now owns 56,115 shares of the biopharmaceutical company’s stock worth $5,183,000 after buying an additional 177 shares during the period. Range Financial Group LLC lifted its holdings in Gilead Sciences by 285.3% in the 4th quarter. Range Financial Group LLC now owns 10,626 shares of the biopharmaceutical company’s stock valued at $982,000 after purchasing an additional 7,868 shares in the last quarter. First County Bank CT boosted its position in Gilead Sciences by 2.9% during the fourth quarter. First County Bank CT now owns 23,760 shares of the biopharmaceutical company’s stock worth $2,195,000 after acquiring an additional 680 shares during the last quarter. Spartan Planning & Wealth Management purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at $230,000. Finally, Diversified Trust Co grew its holdings in Gilead Sciences by 3.0% in the 4th quarter. Diversified Trust Co now owns 34,455 shares of the biopharmaceutical company’s stock valued at $3,183,000 after buying an additional 1,019 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on GILD shares. JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Piper Sandler raised their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Citigroup began coverage on Gilead Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $125.00 price objective on the stock. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Finally, Bank of America restated a “buy” rating and set a $109.00 price objective on shares of Gilead Sciences in a research note on Tuesday, December 10th. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $97.96.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 453,734 shares of company stock worth $41,902,086. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Price Performance

Shares of GILD stock traded up $0.24 during mid-day trading on Friday, hitting $89.38. 2,007,397 shares of the stock traded hands, compared to its average volume of 5,029,229. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The company’s 50-day simple moving average is $91.93 and its 200-day simple moving average is $83.06. The firm has a market cap of $111.39 billion, a price-to-earnings ratio of 993.11, a price-to-earnings-growth ratio of 2.24 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period last year, the firm posted $2.29 earnings per share. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were issued a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.45%. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.